| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 17(1); 1985 > Article
Journal of the Korean Cancer Association 1985;17(1): 59-72.
인체 대장 선암유래 세포주 ( SC-1 ) 의 대한 시험관내 항암제 감수성 검사에 관한 실험적 연구
양대현, 박재갑, 김진복
In vitro Chemosensitivity Test of Cell Line ( SC-1 ) Derived from Human Colon Adenocarcinoma
Dae Hyun Yang, Jae Gahb Park, Jin Pok Kim
In vitro chemosensitivity tests of SC-I (Seoul National University, Adenocarcinoma of the Colon) with 24 hour exposure of 6 anticancer agents (adriamycin, 5FU, cisplatin, methotre- xate, mitomycin and BCNU) were done by succinic dehydrogenase inhibition test and dye exclusion method. And also the inhibition of CEA production of SC-I, which can produce large amount of CEA, by these anticancer agents was measured. SC-I was used as the suspension of 3.0x 10 cells/ml which was near the natural in vitro cell concentration and easily available. And 2 in vicro anticancer drug cancentrations were applierl as an actual experimental concentration or a base concentration for concentration and dilution;ane in vitro concentration was the usual high clinical daae di.vided by 50, 000 ml which is the estimated body water of the patient of 70kg body weight, and the other is the peak plasma concentration clinically achievable. The auccinic dehydrogenase activity was measured by obtaining optic densities, which is related with the amaunt of formazan formed by the activity of succinic dehydrogenase; and succinic rlehydrogenase inhibition index was calculated as (a-p)/(a-m) x100% (p:oPtic density of anticancer agent and tetrazolium chloride applied SC-I suspension, a:optic density of tetrazolium chlorirle applied SC-I cell suspension, m:optic density of cell suspension alone). By dye exciusion method using trypan blue, cell viability was measured. And cytotoxicity index was calculated as(Vb-Va)/Vbx100%(Va:cell viability of anticancer agent exposed SC-I suspension, Vb: cell viahility of free SC-I suspension), CEA levels of SC-1 cell suspenion were measured by radioimmunoas""ay in the supernatant after centrifugation. And CEA inhibition index was calculaterl as 100%- (CEAa-basal CEA)/ (CEAb basal CEA) x100% (basal CEA: before exposure to drug, CEAa: CEA after 24 hour incubation with anticancer drug, CEAb: CEA of simply incubated cell suspension) The results were as foliows, 1) In dose response curve, succinic dehydrogenase inhibition index and cytotoxicity index were increase with the increase of the doae of 6 anticancer drugs. 2) The supernatant of SC-I suspension had high level of CEA, about 50 ng/10 cells or more in 6 all measured subcultures. 3) At the concentration of the usual high clinical dose divided by 50,000 ml; adriamycin and 5FU were the sensitive an.ticancer agents for the SC-I of subculture 34 with sensitivity criteria af succinic dehydrogenase inhibition index40%, and adriamycin, 5FU and BCNU were the sensitive agents with sensitivity criteria of CEA inhibition index-50. At the peak plasma concentration achievable; adriamycin, methotrexate and 5FU were the sensitive anticancer agents for the SC-I of subculture 34 with sensitivity criteria of succinic dehydrogenase inhibition index40%, and BCUN, adriamycin and GFU were the sensitive agents with sensitivity criteria of CEA inhibitian index>=50%. Between the 2 single in vitro concentratians the changes in the sensitivities of the drugs were rather acceptible in selection of the sensitive drugs by succinic dehydrogenase inhibition test and CEA inhibition test. 4) Of the in vitro chemsensitivity tests of SC-I; CEA inhibition test was very sensitive and its role as an efficient in vitro chemosensitivity test for colorectal cancer was anticipa- ted, and succinic dehydrogenase inhibition test was rather sensitive but the relative differe- nces in responses between sensitive drugs and resistant drugs were small. And dye exclusion method showed poor response. 5) It waa thought that the CEA inhibition test af the established colorectal cancer cell line (such as SC-I) would be a valuable tool in screening of anticancer drugs, and research of cambination chemotherapy regimen and exposure schedule of chemotherapy for colorectal cancer.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI